Tune In: Field Trip has eight ketamine-assisted therapy clinics across North America.
Seth Wilson, a 41-year-old sommelier in Chicago, has been dealing with depression and anxiety since he was 13 years old. Wilson learned to live with his panic attacks until his mother passed away and they gradually got worse. He had been on some kind of antidepressant or anti-anxiety medication for over a decade, but he wasnt getting the help he needed. One day last spring, he went to a Field Trip Health clinic overlooking Lake Michigan, put on eyeshades, headphones, leaned back in a comfy zero-gravity leather chair and got an injection of the dissociative anesthetic ketamine. Within seconds he was blasted to the cosmos and entered the event horizon of a black hole.
Instead of being overcome with fear and panic, he was washed over by waves of awe and a feeling that theres something beyond life as we know it. I sound like a doting hippie, but I realized that nothing else matters except for love and gratitude, says Wilson.
Since seeking ketamine-assisted therapy, which includes six infusions, followed by talk therapy sessions, he has cut his dose of anti-anxiety medication in half. Before undergoing ketamine therapy, he had wanted to do therapy with other psychedelics like psilocybin, the active ingredient in magic mushrooms, or LSD. Even though biotech startups are racing to develop medicines based on psilocybin, MDMA and other psychedelic molecules and get them approved by the U.S. Food and Drug Administration, these substances are still illegal in the U.S. But ketamine has a big advantage over other psychedelicsits legal.
Thanks to its legal status and the psychedelic renaissance underway, ketamine-assisted therapy has reached the mainstream. And companies like Field Trip Health, Novamind, Nushama, Mindbloom and others are stepping on the gas and expanding locations and services to patients across the country.
While psilocybin, MDMA and LSD grab most of the headlines for the promising clinical results as potential treatments for depression, post-traumatic stress disorder and other mental health issues, ketamine is able to cash in on the growing interest in psychedelics.
Ketamine also has another advantage over other psychedelics: its short-acting. One of the biggest hurdles in widespread treatment of psychedelic-assisted therapy for drugs like psilocybin, LSD and MDMA is the duration of the experience, which can range from 4 to 12 hours. But for ketamine, a patient can be in and out of one of these swanky clinics in two hours. (Some companies are trying to remove the psychedelic experience altogether, while others are modifying psychedelics molecules to make the trip shorter.)
Ronan Levy, the CEO of Field Trip Health, which has eight clinics across the U.S. and Canada, says hes seeing an increase in the number of patient visits across every location. The company says it will expand to 20 locations by the end of 2021 and scale to 75 clinics by 2024. The demand for psychedelic-assisted therapy is growing, and while FDA-approved psilocybin or MDMA is still years away, ketamine is already here.
When people realize that there is a legal option available right now that can be provided with medical supervision and professional therapy, it becomes a really appealing option, says Levy. Its the most easily accessible, legal option, which is leading to the boom around ketamine right now.
Field Trip is not the only one benefiting from how ketamine has gone mainstream.
Novamind, which owns a Utah-based chain of clinics under the name Cedar Psychiatry that offers ketamine-assisted therapy, is trying to keep up with the demand. Earlier this year, the company said it had a two-week wait time at each of its clinics. Last year, it saw 20,000 patients and says by the end of the year Novamind is on pace to see 65,000 patients, a 225% increase.
Yaron Conforti, the CEO of Novamind, says ketamine is enjoying a moment, especially as mental health awareness has increased during the pandemic and more people are looking for different types of treatment.
Ketamine is having its time, says Conforti. Its happening now.
Ketamine has largely lost its stigma as a party drug and a horse tranquilizer. But it took time, even though ketamine has been an FDA-approved anesthetic for decades used on the battlefield, in pediatrics and yes, by veterinarians. Much of the growing interest in ketamine is thanks to the FDA approving Spravato, which is a nasal spray that contains a ketamine derivative called esketamine, in 2019. Spravato, which is made by Johnson & JohnsonsJanssen, is approved to treat adults with treatment-resistant depression and depressive symptoms in adults with major depressive disorder with suicidal thoughts or behavior.
Craig Chepke, a psychiatrist with his own practice in Huntersville, North Carolina, says the FDA approving Spravato, and the fact that insurance companies are now covering the drug, has helped usher in the mainstreaming of ketamine treatments. When Spravato was first approved in 2019, hed only see about two patients a week. Hes now seeing close to ten patients a day.
I dont think anyone can ignore it at this point, says Chepke. If it's not on the mind of every psychiatrist who treats treatment-resistant depression, it darn better be because it helps. It doesnt help everybody, but it does help a lot of these patients who really have nothing else left and who have exhausted almost every avenue of treatment.
But the best part of ketamine-assisted therapy, Chepke says, is more of an abstract notion.
Its the spark of hope, says Chepke. I always said the most important thing a doctor can give a patient is not a prescriptionit's hope. And for many people, some of these psychedelic substances are giving them hope.
Another reason why ketamine-assisted therapy is getting more and more popular is because of positive patient outcomes.
Day to day, the majority of our clients walk in depressed and walk out feeling considerably better, if not completely undepressed, says Ben Medrano, a psychiatrist whos the medical director at Field Trip. Its commonplace for us.
But ketamine is just the first step for companies like Field Trip.Itwill eventually expand to offer other psychedelic drugs if they become approved by the FDA or allowed under state programs. (Oregon is in the process of launching a psilocybin-assisted therapy program.) Levy says the best way to think about Field Trip is a psychedelic therapy platform that will offer patients a menu of psychedelic compounds to be used in therapy.
Our clinical infrastructure will be molecule agnostic, says Levy. Different molecules will serve different patients; different indications and we intend to support any psychedelic-assisted therapies. It could be MDMA, psilocybin or our own novel molecules, and if LSD gets approved for something, fantastic.
Promising studies out ofJohns Hopkins,Imperial College London,New York University, theMultidisciplinary Association for Psychedelic Studies(MAPS) and other institutions have found therapeutic potential of drugs like psilocybin and MDMA for various conditions, including depression, end-of-life anxiety, post-traumatic stress disorder, obsessive-compulsive disorder and nicotine and alcohol dependence.
Field Trips big plan is to bring its own hallucinogenic compound to market. It is developing a psychedelic molecule that targets the 5HT-2A receptor in the brain, the same one psilocybin targets, and plans to pursue FDA approval. The compound, which the company has named FT-104 for the time being, packs a trip thats only two hours long, or half the time an experience with magic mushrooms lasts. The company plans to launch phase 1 clinical trials early next year.
During Wilsons last ketamine session, he set an intention to see his late mother. Once the ketamine took hold, his mother took him to experience her birth and showed him the afterlife. He says the experience helped him deal with the trauma of his mothers death, but also helped him manage his anxiety and depression by showing him there is something beyond the physical world.
Were all searching for the ineffable and its so deeply personal, he says. I think the word God can be triggering for people, but its about this trust and faith that there is something bigger and grander than ourselves. And that this physical world doesnt matter and all our problems dont matterthere is something greater.
Go here to read the rest:
Why Ketamine-Assisted Therapy Has Gone Mainstream - Forbes
- Psychedelic Drug Effects, Side Effects & Dangers - January 25th, 2023
- Psychedelics Decriminalization Project In Berkeley, Cal Includes ... - January 6th, 2023
- Ancient mummified child was drugged with psychedelics before ritual ... - December 14th, 2022
- The therapeutic potential of psychedelics - Science - December 14th, 2022
- Changing Lives with Psychedelics: How Connecticut researchers are using magic mushrooms to help people overcome depression, OCD - WTNH.com - November 19th, 2022
- Penis Envy Mushroom | Legal Psychedelics | Magic Mushroom - November 7th, 2022
- Psychedelics. Discussing natural and synthetic friends. Science, News ... - November 5th, 2022
- The Harms of Psychedelics Need to Be Put Into Context - WIRED - November 5th, 2022
- Packers' Aaron Rodgers says psychedelics led to his back-to-back MVP ... - October 28th, 2022
- With Promise of Legalization, Psychedelic Companies Joust Over Future Profits - The New York Times - October 25th, 2022
- How do psychedelics work? This brain region may explain their effects - PBS - October 21st, 2022
- Why is the American right suddenly so interested in psychedelic drugs? - The Guardian - October 19th, 2022
- Can Psychedelics Cure? Science Is on the Verge of Finding Out - Newsweek - October 19th, 2022
- Large national survey suggests that the use of psychedelics is not associated with lifetime cancer development - PsyPost - October 19th, 2022
- This Pharma Company Just Scored Another Psychedelics Patent And Set Its Sights On 70 More - Small Pharma - Benzinga - October 19th, 2022
- What Made the Mushrooms Magic: Psychedelic Study Explores the Odd Evolution of Mind-Altering Fungi - The Debrief - October 19th, 2022
- Psychedelics And Wellness: The Healing Company Buys PepsiCo-Backed Superfoods Company - (HLCO) - Benzinga - October 19th, 2022
- What's on the Colorado ballot? Housing, psychedelics, school meals, alcohol, taxes and more | FOX31 Denver - FOX 31 Denver - October 19th, 2022
- DoseConnect to Sponsor the Tech Stage at Wonderland Miami by Microdose - Benzinga - October 19th, 2022
- What Is Going on With Bright Minds (DRUG) Stock Today? - InvestorPlace - October 19th, 2022
- Psychedelics May Ease Fear of Death and Dying - October 17th, 2022
- TDR's Top 5 Psychedelic Developments For The Week Of October 10 - The Dales Report - October 17th, 2022
- DEA Wants To Boost Production Of Cannabis & Psychedelics For Research In 2023 - Benzinga - October 17th, 2022
- Talk set to explore psychedelics and mental health - Reading Today - October 17th, 2022
- Silo Wellness Closes Acquisition of Dyscovry Science and Its Psilocybin Pharmaceutical Biosynthesis and Research Portfolio - Yahoo Finance - October 17th, 2022
- How does psilocybin rewire the brain? - Open Access Government - October 17th, 2022
- HYTN Awarded Controlled Drugs and Substances Dealers License Allowing for Production and Sale of Psilocybin - Yahoo Finance - October 17th, 2022
- The Healing Company acquires leading superfoods business, Your Super, and lands $150M credit facility to expand community of brands - Yahoo Finance - October 17th, 2022
- 5 Things to Know About Colorados Psychedelics Ballot Initiative - Kaiser Health News - October 15th, 2022
- Psilocybin Retreats - a Focal Point of the Growing Psychedelic Market - The Hype Magazine - October 15th, 2022
- 10 must-read weed and psychedelics books from the last decade - Leafly - October 15th, 2022
- Treating Postpartum Depression with Psychedelics - Psychedelic Spotlight - October 15th, 2022
- Clerkenwell Health raises 2.1M to test the new wave of psychedelics treatments - TechCrunch - October 15th, 2022
- Toronto Psychedelic Exhibition features the Art and History of Psychedelics - Psychedelic Spotlight - October 15th, 2022
- Elon Musk's 'Exploratory Journeys' And Charts Explaining Benefits Of Psychedelics Over Alcohol - Tesla (N - Benzinga - October 15th, 2022
- ALTRD.TV's Open Minds Documentary Explores the Promising Future of Psychedelic Medicine - Business Wire - October 15th, 2022
- IntelGenxs Collaboration with atai Life Sciences Culminates in the Initiation of First-in-Human Clinical Study of an Oral Thin Film Psychedelic Drug... - October 15th, 2022
- Psychedelics Companies And IPs: An Extended Patent Application To Protect Multiple LSD Derivatives - Bett - Benzinga - September 29th, 2022
- Congressman Says Psychedelics Show 'Real Promise' As Alternative Therapies At Committee Hearing - Marijuana Moment - September 29th, 2022
- Psychedelics and mental health: the potential, risks and hype - WHYY - September 27th, 2022
- Is Now a Good Time to Invest In Psychedelics Stocks? - The Motley Fool - September 27th, 2022
- I went to the only psychedelic dispensary in North Americaheres how they do it - The Manual - September 27th, 2022
- Psychedelic drugs: how to tell good research from bad - The Conversation Indonesia - September 27th, 2022
- The Connection Between Psychedelics and Grief - Psychedelic Spotlight - September 27th, 2022
- Effects of LSD and Psilocybin in Healthy Participants - Psychiatric Times - September 27th, 2022
- Cannabis And Psilocybin May Have Helped This Woman's Breast Cancer Treatment - IFLScience - September 27th, 2022
- Ketamine, psilocybin and ecstasy are coming to the medicine cabinet - Yahoo Finance - September 27th, 2022
- American Legion and Reality Center Partner to Provide Patented, Drug-Free Psychedelic Experience to Veter - Benzinga - September 27th, 2022
- Let's Bring the Informed Consent Process Out of the Shadows - Undark Magazine - September 27th, 2022
- Nicole Krauss on Death, Birth, and Middle Age - The New Yorker - September 27th, 2022
- Daily Skimm: Psychedelics, The DOJ, and iMessages - theSkimm - September 15th, 2022
- Inside the UK's new psychedelic drug trial clinic trying to treat depression and anxiety - iNews - September 15th, 2022
- What A Trip: Delix Therapeutics is Treating Mental Health at Scale with Psychoplastogens - Genetic Engineering & Biotechnology News - September 15th, 2022
- HealingMaps Announces $1 Million in Seed Funding to Power Growth in Psychedelic Therapy Industry - Yahoo Finance - September 15th, 2022
- Nav Talks The Moment He Realized He Made It; It Involves Psychedelics - UPROXX - September 15th, 2022
- Psychedelics and Psychedelic-Assisted Psychotherapy - September 7th, 2022
- Preparing for a new era of psychedelic treatment - The Hub at Johns Hopkins - September 7th, 2022
- Toronto is getting a trippy psychedelics immersive exhibition this month - Curiocity - September 7th, 2022
- Xtalks to host upcoming webinar on psychedelic know-how - Mugglehead - September 7th, 2022
- An immersive psychedelic exhibition is opening in Toronto this month | Listed - Daily Hive - September 7th, 2022
- Netflixs How to Change Your Mind Says Drugs Are the Answer Are They Right? - Goalcast - September 7th, 2022
- Yeah, Mental Health, Bro, It Starts With Self-Love | Aaron Rodgers Says His Use Of Psychedelics Has Increased His Passion For Life And The Game Of... - September 7th, 2022
- Delic Executive Chairman Matt Stang Named to World Biz Magazine's Top 100 CEOs in Innovation - Yahoo Finance - September 7th, 2022
- Cannabis and Hallucinogens Are Being Consumed at the Highest Rates on Record by Today's Young Adults - Cannabis Science and Technology - September 7th, 2022
- Aspen considers the value of psychedelics for mental wellness - The Aspen Times - August 29th, 2022
- Oregon's Psychedelics Law Comes Down To Individuals: Which Counties Will Ban Them? - Benzinga - August 29th, 2022
- The Black mothers finding freedom in mushrooms: They give us our power back - The Guardian - August 29th, 2022
- Psychedelic Water CEO Pankaj Gogia Talks About The Future Of Psychedelics - Exclusive - Health Digest - August 2nd, 2022
- Biden Administration Says Task Force Is Needed to Advance Psychedelics Research - Green Entrepreneur - August 2nd, 2022
- Legalizing the trip: One 'shroom advocate's playbook - POLITICO - August 2nd, 2022
- 'The result was a rebirth. I finally got where I wanted to go': Celebs who have tried psychedelics - The Daily Post-Athenian - August 2nd, 2022
- Texas' first Ceremonial Psychedelic Treatment Center WITHIN opens in Austin - PR Web - August 2nd, 2022
- Postdoctoral Research Fellow in Psychedelics, Neurodevelopment and Electrophysiology job with UNIVERSITY OF SYDNEY | 303322 - Times Higher Education - August 2nd, 2022
- Unlimited Sciences Announces Groundbreaking New Study to Observe Ayahuasca's Effects on Trauma - Business Wire - August 2nd, 2022
- Good Trip? How Psychiatrists Got Serious About Using Psychedelics to Treat Mental Health - Robb Report - July 25th, 2022
- The hope and hype of psychedelic therapy - ABC News - July 25th, 2022
- Microdosing Psilocybin Mushrooms May Improve Mental Health and Mood - Healthline - July 25th, 2022
- TDR's Top 5 Psychedelic Developments For The Week Of July 18 - The Dales Report - July 25th, 2022
- Psyched Up: The race to make psychedelic drugs part of mainstream medicine - ABC News - July 25th, 2022
- Keeping the Hippie Dream Alive - The New York Times - July 25th, 2022